Responsible Center: NASA ARC
Grant Monitor: Ronca, April Elizabeth
Center Contact: 650.400.6019 april.e.ronca-1@nasa.gov
Unique ID: 9426
|
Solicitation / Funding Source: 2012 Crew Health NNJ12ZSA002N
Grant/Contract No.: NNX13AQ92G
Project Type: GROUND
Flight Program:
TechPort: No |
No. of Post Docs: 0
No. of PhD Candidates: 0
No. of Master's Candidates: 0
No. of Bachelor's Candidates: 0
|
No. of PhD Degrees: 0
No. of Master's Degrees: 0
No. of Bachelor's Degrees: 0
|
|
Human Research Program Elements: |
(1) HHC:Human Health Countermeasures
|
|
Human Research Program Risks: |
(1) Bone Fracture:Risk of Bone Fracture due to Spaceflight-induced Changes to Bone (2) Osteo:Risk Of Early Onset Osteoporosis Due To Spaceflight
|
|
Human Research Program Gaps: |
(1) Osteo 5:We need an inflight capability to monitor bone turnover and bone mass changes during spaceflight. (2) Osteo 7:We need to identify options for mitigating early onset osteoporosis before, during and after spaceflight.
|
|
Flight Assignment/Project Notes: |
NOTE: Extended to 12/31/2015 per A. Chu/ARC and NSSC information (Ed., 7/28/15)
NOTE: Extended to 9/30/2015 (original end date was 9/30/2014) per NSSC information and A. Chu/ARC (Ed., 9/10/14) |
|
Task Description: |
Antihypertensive medications affecting the renin-angiotensin system (RAS), specifically angiotensin converting enzyme inhibitor (ACEI), have been documented to decrease bone turnover in animals, and improved bone mineral density (BMD) in preliminary human studies. We propose a randomized trial to collect pilot data in 30 men and 30 women (15 treated with ACEI and 15 not treated with RAS related medications) to investigate if ACEI prevents bone loss by decreasing bone turnover. We hypothesize that ACEI use for 3 months to treat hypertension (HTN) in older adults will decrease bone turnover by decreasing bone resorption, the primary factor in spaceflight induced bone loss. These results could provide another tool in protecting bone health of astronauts, using a pharmacological agent with very few side effects, which is a significant concern of agents currently being tested. Further, these data may also help understand variability in existing spaceflight data, where crewmembers may have taken antihypertensive medications, which may have confounded results of ongoing studies. Beyond NASA, the clinical implications of this study for the general population are significant. |
|
Research Impact/Earth Benefits: |
Provide knowledge of prevention in bone loss due to old age. |